MarketInOut Stock Screener Log In | Sign Up

Alzamend Neuro Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/30/2026
Alzamend Neuro Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization5.84 mln
Float4.70 mln
Earnings Date12/09/2026

Piotroski F-Score

3 / 9
Below average

Relative Strength

20 / 100
Significantly lagging

ROE

-247
Deeply negative

ROA

-174
Deeply negative

Business Description

Alzamend Neuro is an Atlanta-based company, founded in 2016, that is developing new medical treatments for brain-related conditions such as Alzheimer's disease, bipolar disorder, PTSD, and major depression. Its lead treatment, AL001, combines lithium, proline, and salicylate into a single therapy, while its second program, ALZN002, works by training the body's own immune system to fight Alzheimer's disease. Both treatments are currently being tested in clinical trials.

Key Fundamentals

EPS-2.30
ROE-247
ROIC-2,654
ROA-174
Interest Cover819
EBITDA, mln-8.98
EV / EBITDA0.29
EV / EBIT0.29

Quote Details

Last 1.21
Change -0.01 (-0.82%)
Open 1.29
Volume 25,022
Turnover 30,277
Average Volume 28,050

Financial Ratios

Leverage Ratio1.47
Current Ratio3.01
Price / Book0.94
Price / Tangible Book0.94

Financial Strength

Piotroski F-Score 3 / 9
Short Ratio0.41
Short % of Float0.73

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 7.08% 91 / 100   
1 Month -8.33% 32 / 100   
2 Months -9.7% 32 / 100   
6 Months 8.04% 81 / 100   
1 Year -50.61% 18 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog